Effect of <italic style="font-style: italic">Jianpi Jiedu Formula </italic>（健脾解毒方） on Survival Time in Advanced Colorectal Cancer Patients with Synchronous and Metachronous Metastases： A Retrospective Analysis

DU Meilu; HOU Fenggang; SHI Qi; HAN Susu; YANG Yi; JIA Jianing; LIU Xing; SHI Chuan; YIN Xiaoling

doi:10.13288/j.11-2166/r.2023.08.012

您当前的位置：

首页 >

文章列表页 >

Effect of Jianpi Jiedu Formula （健脾解毒方） on Survival Time in Advanced Colorectal Cancer Patients with Synchronous and Metachronous Metastases： A Retrospective Analysis

更新时间：2023-04-14

- Effect of Jianpi Jiedu Formula （健脾解毒方） on Survival Time in Advanced Colorectal Cancer Patients with Synchronous and Metachronous Metastases： A Retrospective Analysis
- Journal of Traditional Chinese Medicine Vol. 64, Issue 8, Pages: 820-826(2023)
- 作者机构：
  
  上海中医药大学附属市中医医院，上海市静安区芷江中路274号，200071
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2023.08.012
  CLC：
- Received：26 May 2022，
  
  Revised：2023-02-10，
  
  Published：17 April 2023
- 稿件说明：
移动端阅览
杜美璐,侯风刚,石齐等.健脾解毒方对晚期大肠癌同时性和异时性转移患者生存时间影响的回顾性分析[J].中医杂志,2023,64(08):820-826.

DU Meilu,HOU Fenggang,SHI Qi,et al.Effect of Jianpi Jiedu Formula （健脾解毒方） on Survival Time in Advanced Colorectal Cancer Patients with Synchronous and Metachronous Metastases： A Retrospective Analysis[J].Journal of Traditional Chinese Medicine,2023,64(08):820-826.
杜美璐,侯风刚,石齐等.健脾解毒方对晚期大肠癌同时性和异时性转移患者生存时间影响的回顾性分析[J].中医杂志,2023,64(08):820-826. DOI： 10.13288/j.11-2166/r.2023.08.012.

DU Meilu,HOU Fenggang,SHI Qi,et al.Effect of Jianpi Jiedu Formula （健脾解毒方） on Survival Time in Advanced Colorectal Cancer Patients with Synchronous and Metachronous Metastases： A Retrospective Analysis[J].Journal of Traditional Chinese Medicine,2023,64(08):820-826. DOI： 10.13288/j.11-2166/r.2023.08.012.

摘要

目的

观察健脾解毒方对晚期大肠癌同时性转移和异时性转移患者生存情况的影响。

方法

回顾性收集确诊的晚期大肠癌患者的一般资料及病理类型、组织分化、转移部位、既往治疗史、既往病史、确诊时间、复发转移时间、死亡时间，确诊6个月内出现转移为同时性转移，确诊6个月后出现转移为异时性转移。根据是否服用健脾解毒方将入组患者分为健脾解毒方组和对照组，同时性转移患者分为健脾解毒方1组和对照1组两个亚组；异时性转移患者分为健脾解毒方2组和对照2组两个亚组。采用倾向性评分匹配平衡组间协变量，以生存时间为主要结局指标。采用Kaplan-Meier曲线分析比较健脾解毒方组和对照组患者生存时间及亚组患者生存时间，Cox比例风险回归模型分析协变量（年龄、性别、肿瘤原发部位、分化级别、病理类型、转移部位、手术史、化疗史、合并症）对晚期大肠癌患者的生存时间的影响。

结果

匹配前共纳入874例患者，匹配后纳入770例，其中同时性转移患者290例（健脾解毒方1组130例，对照1组160例），异时性转移患者480例（健脾解毒方2组262例，对照2组218例）。健脾解毒方组患者中位生存时间为38个月，对照组为30个月，死亡风险比HR为0.77（95%

：0.67~0.89，

＜0.001）。健脾解毒方1组的中位生存时间为20个月，对照1组为14个月，两组比较差异有统计学意义（

＜0.05），死亡风险比HR为0.80（95%

：0.63~1.01）；健脾解毒方2组中位生存时间为49个月，对照2组为37个月，两组比较差异有统计学意义（

＜0.01），死亡风险比HR为0.79（95%

：0.66~0.95）。同时性转移和异时性转移患者中位生存时间分别为16个月和42个月，死亡风险比HR为2.23（95%

：1.92~2.59，

＜0.001）。

结论

健脾解毒方可以延长晚期大肠癌异时性转移患者生存时间，降低同时性转移患者死亡风险，且异时性转移患者从健脾解毒方中获益更多。

Abstract

Objective

To explore the effect of

Jianpi Jiedu Formula

（健脾解毒方， JJF） on survival time in advanced colorectal cancer with synchronous and metachronous metastases.

Methods

Data were collected from the clinical records of patients with advanced colorectal cancer， including the general information and pathological type， tissue differentiation， metastatic site， previous treatment history， past medical history， diagnosis time， recurrence and metastasis time， and death time. Patients were divided into the synchronous and metachronous metastasis， with synchronous disease defined as distant metastases occurring within， and metachronous disease beyond 6 months of the primary diagnosis. According to whether or not JJF was taken， patients were divided into JJF group and control group （without JJF）， and further JJF group1 and control group1 in patients with synchronous metastasis， and JJF group2 and control group2 in patients with metachronous metastasis. Propensity score matching （PSM） was used to further balance the covariates between groups. Survival time was the primary outcome. In addition， we used Kaplan-Meier curve to compare the survival time between JJF and control groups， as well as the Cox proportional hazards regression model to analyze the influence of covariates including age， gender， primary tumor site， differentiation grade， pathological type， metastatic site， operation history， chemotherapy history， and comorbidities on the overall survival in advanced colorectal cancer.

Results

A total of 874 patients were included before matching， and 770 patients remained after PSM including 290 patients with synchronous metastases （130 cases in the JJF group1 and 160 cases in the control group1） and 480 patients with metachronous metastases （262 cases in the JJF group2 and 218 cases in the control group2）. The medium survival time for patients in the JJF group was 38 months， while that in the control group was 30 months， with the hazard ratio （HR） of 0.77 （95%

0.67-0.89，

＜0.001）. The medium survival time in the JJF group1 and control group1 was 20 months and 14 months， respectively， and the difference was significant （

＜0.05） with a HR of 0.80 （95%

0.63-1.01）. The medium survival time was 49 months in the JJP group2 and 37 months in the control group2 with significant difference （

＜0.01）， and HR was 0.79 （95%

0.66-0.95）. For synchronous and metachronous metastases， the medium survival time was 16 months and 42 months， respectively， and risk ratio of death was 2.23 （95%

1.92-2.59，

＜0.001）.

Conclusion

JJF can prolong the survival time of advanced colorectal cancer patients with metachronous metastases and reduce the risk of death in patients with synchronous metastases， and metachronous metastases patients can benefit more from JJF than synchronous metastases.

关键词

Keywords

references

SIEGEL RL ， MILLER KD ， FUCHS HE ， et al . Cancer Statistics， 2021 ［J］. CA Cancer J Clin ， 2021 ， 71 （ 1 ）： 7 - 33 .

郑莹，王泽洲 . 全球结直肠癌流行数据解读［J］ . 中华流行病学杂志， 2021 ， 42 （ 1 ）： 149 - 152 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）常见恶性肿瘤诊疗指南2020 ［M］. 北京：人民卫生出版社， 2020 ： 433 - 446 .

BA L ， WANG Q ， WANG H ， et al . Survival analysis and prognostic factors of palliative radiotherapy in patients with metastatic colorectal cancer： a propensity score analysis ［J］. J Gastrointest Oncol ， 2021 ， 12 （ 5 ）： 2211 - 2222 .

JOHARATNAM-HOGAN N ， WILSON W ， SHIU KK ， et al . Multimodal Treatment in Metastatic Colorectal Cancer （mCRC） improves outcomes-The University College London Hospital （UCLH） experience ［J］. Cancers （Basel）， 2020 ， 12 （ 12 ）： 3545 .

吴乐霞，张华堂，方灿途，等 . 中医辨治结直肠癌肝转移的研究进展［J］. 中医肿瘤学杂志， 2021 ， 3 （ 3 ）： 1 - 5 .

王曦妤 . 晚期结直肠癌方药挖掘、实验验证及其潜在机制分析［D］. 上海：上海中医药大学， 2021 .

刘曼曼，侯风刚 . 王羲明教授治疗大肠癌经验撷菁［J］. 临床医药文献电子杂志， 2017 ， 4 （ 68 ）： 13441 - 13442 .

ENGSTRAND J ， STRÖMBERG C ， NILSSON H ， et al . Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition ［J］. World J Surg Oncol ， 2019 ， 17 （ 1 ）： 228 .

MA CX ， GUAN X ， WEI R ， et al . The distinction of clinicopathological characteristics， treatment strategy and outcome in colorectal cancer patients with synchronous vs. metachronous bone metastasis ［J］. Front Oncol ， 2020 ， 10 ： 974 . doi： 10.3389/fonc.2020.00974 http://dx.doi.org/10.3389/fonc.2020.00974 .

HOLCH JW ， DEMMER M ， LAMERSDORF C ， et al . Pattern and dynamics of distant metastases in metastatic colorectal cancer ［J］. Visc Med ， 2017 ， 33 （ 1 ）： 70 - 75 .

TAN EK ， OOI L . Colorectal cancer liver metastases- understanding the differences in the management of synchronous and metachronous disease ［J］. Ann Acad Med Singap ， 2010 ， 39 （ 9 ）： 719 - 733 .

周岱翰 . 中医肿瘤学［M］. 广州：广东高等教育出版社， 2007 ： 213 - 215 .

MOR V ， LALIBERTE L ， MORRIS JN ， et al . The karnofsky performance status scale. An examination of its reliability and validity in a research setting ［J］. Cancer ， 1984 ， 53 （ 9 ）： 2002 - 2007 .

韦堂军，赵智强 . 周仲瑛运用抗癌解毒法治疗肠癌经验［J］. 中医杂志， 2015 ， 56 （ 2 ）： 99 - 101 .

ZHENG P ， REN L ， FENG Q ， et al . Differences in clinical characteristics and mutational pattern between synchronous and metachronous colorectal liver metastases ［J］. Cancer Manag Res ， 2018 ， 10 （ 10 ）： 2871 - 2881 .

ZHANG C ， CUI M ， XING J ， et al . Clinicopathologic features and prognosis of synchronous and metachronous multiple primary colorectal cancer ［J］. Clin Transl Oncol ， 2021 ， 23 （ 2 ）： 335 - 343 .

COLLOCA GA ， VENTURINO A ， GUARNERI D . Different variables predict the outcome of patients with synchronous versus metachronous metastases of colorectal cancer ［J］. Clin Transl Oncol ， 2020 ， 22 （ 8 ）： 1399 - 1406 .

BARTOLINI I ， RINGRESSI MN ， MELLI F ， et al . Analysis of prognostic factors for resected synchronous and metachronous liver metastases from colorectal cancer ［J］. Gastroenterol Res Pract ， 2018 ， 11 （ 6 ）： 1 - 14 .

HENTZEN JEKR ， ROVERS KP ， KUIPERS H ， et al . Impact of synchronous versus metachronous onset of colorectal peritoneal metastases on survival outcomes after Cytoreductive Surgery （CRS） with Hyperthermic Intraperitoneal Chemotherapy （HIPEC）： a multicenter， retrospective， observational study ［J］. Ann Surg Oncol ， 2019 ， 26 （ 7 ）： 2210 - 2221 .

BAKKERS C ， LURVINK RJ ， RIJKEN A ， et al . Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases： a population-based study ［J］. Ann Surg Oncol ， 2021 ， 28 （ 13 ）： 9073 - 9083 .

NISHIOKA Y ， MORIYAMA J ， MATOBA S ， et al . Prognostic impact of adjuvant chemotherapy after hepatic resection for synchronous and early metachronous colorectal liver metastases ［J］. Dig Surg ， 2018 ， 35 （ 3 ）： 187 - 195 .

QUIREZE JUNIOR C ， BRASIL AMS ， MORAIS LK ， et al . Metachronous colorectal liver metastases has better prognosis-is it true ［J］. Arq Gastroenterol ， 2018 ， 55 （ 3 ）： 258 - 263 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Changweiqing （肠胃清） on Transplanted Tumor Growth of Colorectal Cancer Cells and Expression of STAT3 and Bcl-2 Gene Splicing Isoforms

Survival and Follow-up Visit Condition of Patients with Small Cell Lung Cancer Treated by Integrated Traditional Chinese and Western Medicine based on the Internet Plus Traditional Chinese Medicine Chronic Disease Management Model

A Clinical Observation on Changyi Decoction Combined with Chemotherapy in 209 Cases of Postoperative Colorectal Cancer

Comprehensive Traditional Chinese Medicine Therapeutic Scheme in Maintenance Treatment for Advanced Non-small Cell Lung Cancer: a Multicenter, Large-sample and Prospective Cohort Study

Traditional Chinese Medicine Treatment of Colorectal Cancer Based on the Qi-Blood Theory

Related Author

LIU Hui

XIE Manli

YUAN Xu

LIANG Fang

DENG Wanli

CHEN Bin

Baojin HUA

Rui LIU

Related Institution

Shanghai University of Traditional Chinese Medicine

Putuo Hospital，Shanghai University of Traditional Chinese Medicine

Nanyuan Hospital， Fengtai District

Guang 'anmen Hospital，China Academy of Chinese Medical Sciences

Shuguang Hospital Affiliated to Shanghai University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Effect of Jianpi Jiedu Formula （健脾解毒方） on Survival Time in Advanced Colorectal Cancer Patients with Synchronous and Metachronous Metastases： A Retrospective Analysis

DOI：10.13288/j.11-2166/r.2023.08.012

摘要

Abstract

关键词

Keywords

references